real-time news and commentary for investors
Monday, Aug 27
2012, 5:55 PM
Depomed (DEPO) says Janssen Pharmaceuticals has licensed rights to it's Acuform gastric...
Depomed (DEPO) says Janssen Pharmaceuticals has licensed rights to it's Acuform gastric retentive drug delivery technology. In exchange, DEPO will receive an upfront payment of $10M and a low single-digit royalty on net sales of Nucynta ER in the U.S., Canada and Japan through 2021. Additionally, DEPO will be eligible for a one-time sales milestone after hurdling a specified level of quarterly net sales. Shares +6% AH.